Clinical evaluation of reduced glutathione in the treatment of chronic hepatitis B and drug induced liver disease . Shanghai Jing An Central Hospital, He Nan Provincal Medical Res Institute, Hua Shan Hospital, Chang Zheng Hospital, Shanghai, People's Republic of China

Hepatology ◽  
1993 ◽  
Vol 18 (4) ◽  
pp. A262
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Evaluation ◽  
Reduced Glutathione ◽  
People's Republic Of China ◽  
Central Hospital ◽  
Drug Induced ◽  
Republic Of China

scholarly journals Management of chronic hepatitis B before and after liver transplantation

2017 ◽  
Vol 9 (1) ◽  
pp. 79-84 ◽  
Author(s):  
B Wang ◽  
K Agarwal ◽  
D Joshi
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Public Health Problem ◽  
Global Public Health ◽  
Chronic Hepatitis B Infection ◽  
Before And After ◽  
Related Liver Disease

Chronic hepatitis B infection is a global public health problem associated with significant morbidity and mortality. Persistent infection may evolve to liver cirrhosis and hepatocellular carcinoma, and hepatitis B-related liver disease is a common indication for liver transplantation. Patients with advanced liver disease should be treated with antiviral therapy which may result in clinical improvement. The management of patients after liver transplant then focuses on preventing hepatitis B recurrence in the graft. With the introduction of prophylactic treatment, patient and graft survival has improved significantly. In this review, we will discuss the management of patients with hepatitis B-related cirrhosis, both compensated and decompensated. We also review the management of hepatitis B after liver transplantation.

scholarly journals Scleromyxedema (Arndt - Gottron Syndrome) Developing Under Tenofovir Treatment for Hepatitis B: Unique Presentation in a Bulgarian Patient!

2019 ◽  
Vol 7 (5) ◽  
pp. 782-785 ◽  
Author(s):  
Ivanka Temelkova ◽  
James Patterson ◽  
Georgi Tchernev
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis Virus ◽  
Histological Study ◽  
Drug Induced ◽  
Systemic Involvement ◽  
First Case ◽  
The Face ◽  
Hepatitis B Treatment

BACKGROUND: Scleromyxedema, also referred to as the Arndt-Gottron (S-AG) syndrome or the systemic form of Lichen myxedematosus (LM), is a cutaneous mucinosis with a chronic course and high lethality from systemic involvement of other organs and systems. Interesting in several aspects is the association between scleromyxedema and viral hepatitis about: 1) hepatitis virus infection as a possible etiological factor for the development of scleromyxedema, 2) antiretroviral therapy for the treatment of hepatitis as a method of reversing scleromyxedema and 3) antiviral drugs as inducers of scleromyxedema. CASE REPORT: We present a 53-year old patient who for nine months had been on tenofovir disoproxil 245 mg (0-0-1) therapy for chronic hepatitis B. Three months after the start of antiviral therapy (i.e. for a period of 6 months), the patient observed swelling, itching and hardening of the skin on the face, ears and hands, which subsequently spread throughout the trunk. Subsequent histological study of a skin biopsy revealed changes of scleromyxedema at an advanced stage, though immunoelectrophoresis of serum and urine excluded the presence of paraproteinaemia or para proteinuria. Systemic antihistamine and topical corticosteroid therapy were instituted. Bone involvement with possible plasmacytoma was excluded, and a myelogram showed evidence of an erythroblastic reaction of bone marrow. CONCLUSION: We believe that drug-induced scleromyxedema is a rare but possible phenomenon. We describe the first case of tenofovir-induced scleromyxedema within the framework of chronic hepatitis B treatment.

scholarly journals Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shengnan Li ◽  
Xiehua Zhang ◽  
Qian Li ◽  
Binyue Lv ◽  
Yefan Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Liver Failure ◽  
Chronic Hepatitis B ◽  
Calibration Curve ◽  
Validation Cohort ◽  
External Validation ◽  
Short Term ◽  
Short Term Mortality

Abstract Aims and objectives Acute-on-chronic hepatitis B liver failure (ACHBLF) is a critical clinical syndrome with a high short-term mortality evolved from chronic hepatitis B (CHB)-related liver disease. Prediction of mortality risk and early intervention can improve the prognosis of patients. This study aimed to develop and validate the nomogram for short-time mortality estimation in ACHBLF patients defined according to Asian Pacific Association for the Study of the Liver (APASL). Methods A study of 105 ACHBLF patients with 90-day follow up was performed to develop the nomogram. Patients were randomly assigned to derivation cohort (n = 75) and validation cohort (n = 35) according to 7:3. Concordance index (C-index), calibration curve and decision curve analysis (DCA) were used to evaluate the nomogram. We also compared the nomogram with APASL ACLF research consortium (AARC) score, model for end-stage liver disease (MELD) score, MELD with serum sodium (MELD-Na) score and albumin-bilirubin (ALBI) score. The nomogram was validated using an external cohort including 40 patients. Results The 28-day and 90-day mortality of 105 patients were respectively 49.52% and 55.24%. Albumin (ALB), international normalized ratio (INR) and estimated glomerular filtration rate (eGFR) were independent predictors for 28-day mortality; INR and eGFR were independent predictors for 90-day mortality. C-index of Nomogram-1 for 28-day mortality and Nomogram-2 for 90-day mortality were respectively 0.82 and 0.81. Calibration curve and Hosmer–Lemeshow test (Nomogram-1, 0.323; Nomogram-2, 0.231) showed optimal agreement between observed and predicted death. Areas under receiver operator characteristic curve(AUROC) of Nomogram-1(0.772) and Nomogram-2(0.771) were larger compared with AARC, MELD, MELD-Na and ALBI score. The results were well estimated in the external validation cohort. Conclusions This study highlighted the predictive value of eGFR, and the nomogram based on INR and eGFR could effectively estimate individualized risk for short-term mortality of ACHBLF patients defined according to APASL.

Sign in / Sign up

Export Citation Format

Share Document